RxDoctor Payments Data

Tiffany Genewick, MD

Obstetrics & Gynecology · Lancaster, NYNPI 1144278664

Payments from drug & device makers

$2,123in general payments, 2019–2025

Across 96 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$542
  • Pfizer$337
  • AbbVie$293
  • Therapeuticsmd, Inc.$119
  • Exeltis, USA Inc.$105
  • Revance Therapeutics, Inc.$90
  • plus $637 from 14 others

What the payments were for

  • Food & beverage$1,84087%
  • Education$28313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,123 in reported general payments places this provider in the 80th percentile of 2,673 obstetrics & gynecology providers in New York.

See all obstetrics & gynecology providers in New York

Medicare billing

Part B allowed, 2024
$5,890
Medicare patients
62
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremproEstrogen,con/M-Progest Acet34$18,183
PremarinEstrogens, Conjugated40$16,489
VeozahFezolinetant13$15,007
Estradiol105$8,177
ImvexxyEstradiol14$5,573
Raloxifene Hcl68$2,401
ProgesteroneProgesterone, Micronized35$1,928
DottiEstradiol13$1,089
Clobetasol Propionate25$558
ValacyclovirValacyclovir Hcl30$525
Nystatin38$450
Triamcinolone Acetonide30$256
Alendronate Sodium29$249
Fluconazole59$199
Levothyroxine Sodium11$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPrempro, Premarin$337$34,67274 claims
Astellas Pharma US IncVeozah$542$15,00713 claims
Therapeuticsmd, Inc.Imvexxy$119$5,57314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,673 obstetrics & gynecology providers in New York.

Other obstetrics & gynecology in Lancaster

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →